Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)

Source: Aclaris Therapeutics MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous…...